Seeking Alpha

Akorn (AKRX -8%) gets pummeled on a Deutsche downgrade to Hold, citing its high valuation, a...

Akorn (AKRX -8%) gets pummeled on a Deutsche downgrade to Hold, citing its high valuation, a lack of exclusivity for a generic version of Abbott's (ABT -0.6%) Prometrium, and a weaker than expected Vancomycin launch. The firm also cuts its price target to $14 from $15.
Comments (1)
  • aldenmac
    , contributor
    Comments (2) | Send Message
     
    The key to AKRX is the transition from being solely a domestic generic drug manufacture to their acquisition of Kilitch ( India). The acquisition of Kilitch was a strategic move. Increase capacity, new markets at the expense of lower gross margin but volume. AKRX must make another acquisition to justify it's multiple to carry it thru the lull before the Killitch acquisition numbers kick( Back half of 2013) in.
    23 Jul 2012, 06:28 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|